New drug candidate surovatamig enters first human tests for arthritis and lupus
NCT ID NCT07201558
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-stage study tests a new medicine called surovatamig in 48 adults with rheumatoid arthritis or lupus. The main goal is to check if the drug is safe and tolerable, and how the body processes it. Participants receive increasing doses to find the best and safest level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNBirmingham, Alabama, 35233, United States
-
Research Site
RECRUITINGFullerton, California, 92835, United States
-
Research Site
RECRUITINGAllen, Texas, 75013, United States
-
Research Site
RECRUITINGBirtinya, 4575, Australia
-
Research Site
NOT_YET_RECRUITINGClayton, 3168, Australia
-
Research Site
NOT_YET_RECRUITINGAntwerp, 2020, Belgium
-
Research Site
NOT_YET_RECRUITINGPorto Alegre, 90035-903, Brazil
-
Research Site
NOT_YET_RECRUITINGBeijing, 100034, China
-
Research Site
NOT_YET_RECRUITINGNanjing, 210008, China
-
Research Site
NOT_YET_RECRUITINGBonn, 53127, Germany
-
Research Site
NOT_YET_RECRUITINGMainz, 55131, Germany
-
Research Site
NOT_YET_RECRUITINGMünchen, D-80336, Germany
-
Research Site
NOT_YET_RECRUITINGBarcelona, 08025, Spain
-
Research Site
NOT_YET_RECRUITINGCórdoba, 14004, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28034, Spain
-
Research Site
NOT_YET_RECRUITINGKaohsiung City, 83301, Taiwan
-
Research Site
RECRUITINGKyiv, 04050, Ukraine
-
Research Site
RECRUITINGTernopil, 46002, Ukraine
-
Research Site
RECRUITINGVinnytsia, 21018, Ukraine
Conditions
Explore the condition pages connected to this study.